尿激酶股动脉溶栓治疗脑出血合并DVT研究

Femoral Artery Thrombolysis with Urokinase Combined Low Molecular Weight Heparin in the Treatment of Hypertensive Cerebral Hemorrhage Accompanied with Lower Extremity Deep Vein Thrombosis

目的研究高血压脑出血并DVT患者应用尿激酶股动脉溶栓联合低分子肝素皮下注射治疗的有效性和安全性。方法对60例患者分别采用尿激酶30万U患肢股动脉溶栓联合低分子肝素5000U每日1次皮下注射与单用低分子肝素治疗的疗效比较。结果治疗组7d、14d时的治愈率及7d时的总有效率与对照组比较差异有统计学意义(P<0.01)。无脑出血加重、再出血及其它严重并发症的发生。结论尿激酶股动脉溶栓联合低分子肝素治疗高血压脑出血并DVT患者优于单用低分子肝素,安全有效,降低了肺栓塞和慢性深静脉功能不全的发生。

Objective To investigate the efficacy and safety of treatment of hypertensive intracerebral hemorrhage and deep vein thrombosis of lower extremity（DVT）patients with femoral artery thrombolysis and urokinase combined subcutaneous low molecular weight heparin treatment.Methods The patients were treated with urokinase and low molecular weight heparin（treatment group） or with low molecular weight heparin only（control group）.Efficacy between the two groups were compared.Results In the treatment group,the cure rate of 7 days and 14 days and the total effective rate of 7 days were significantly（P〈0.01） higher than those of the control group.No worsen cerebral hemorrhage,and rebleeding and other serious complications happened.Conclusion The femoral artery thrombolysis with urokinase combined low molecular weight heparin therapy in patients with hypertensive intracerebral hemorrhage combined with DVT was better than low molecular weight heparin alone.Which was safe and effective,and can reduce pulmonary embolism and chronic deep venous insufficiency occurring.